BR112019005039A2 - método de redução dos efeitos colaterais associados à tireóide - Google Patents

método de redução dos efeitos colaterais associados à tireóide

Info

Publication number
BR112019005039A2
BR112019005039A2 BR112019005039A BR112019005039A BR112019005039A2 BR 112019005039 A2 BR112019005039 A2 BR 112019005039A2 BR 112019005039 A BR112019005039 A BR 112019005039A BR 112019005039 A BR112019005039 A BR 112019005039A BR 112019005039 A2 BR112019005039 A2 BR 112019005039A2
Authority
BR
Brazil
Prior art keywords
thyroid
side effects
reduction method
receptor agonists
effects reduction
Prior art date
Application number
BR112019005039A
Other languages
English (en)
Inventor
Lian Brian
Ito Bruce
Masamune Hiroko
Erion Mark
Original Assignee
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Viking Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of BR112019005039A2 publication Critical patent/BR112019005039A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

a presente divulgação é dirigida a métodos de administração de agonistas dos receptores de hormônios da tireóide. a divulgação proporciona métodos em que a atividade dos agonistas do receptor da tireóide dados em melhorar ou curar a obesidade, hiperlipidemia, hipercolesterolemia, diabetes, doença hepática gordurosa não alcoólica, esteato-hepatite não alcoólica, aterosclerose, doença cardiovascular, hipotireoidismo e distúrbios relacionados é mantida, enquanto os efeitos secundários relacionados com a tireóide e relacionados com o eixo da tireóide são reduzidos ou eliminados.
BR112019005039A 2016-09-16 2017-09-13 método de redução dos efeitos colaterais associados à tireóide BR112019005039A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Publications (1)

Publication Number Publication Date
BR112019005039A2 true BR112019005039A2 (pt) 2019-06-25

Family

ID=61619247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005039A BR112019005039A2 (pt) 2016-09-16 2017-09-13 método de redução dos efeitos colaterais associados à tireóide

Country Status (10)

Country Link
US (1) US20190255080A1 (pt)
EP (1) EP3512523A4 (pt)
JP (2) JP2019531346A (pt)
KR (1) KR20190060786A (pt)
CN (1) CN109922812A (pt)
AU (1) AU2017327383B2 (pt)
BR (1) BR112019005039A2 (pt)
CA (1) CA3037146A1 (pt)
MX (2) MX2019003032A (pt)
WO (1) WO2018053036A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
GB2603330B (en) * 2019-08-19 2023-08-09 Hepagene Therapeutics Hk Ltd Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327771D1 (de) * 2002-07-04 2009-07-09 Zealand Pharma As Glp-1 und behandlungsmethode für diabetes
WO2005051298A2 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2606499C (en) * 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
EP2299976A4 (en) * 2008-12-22 2014-07-23 Otonomy Inc SELF-CONTROLLED RELEASE SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR TREATING OTIC DISORDERS
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
EP3445769A4 (en) * 2016-04-22 2020-02-12 Metabasis Therapeutics, Inc. THYROID HORMONE RECEPTOR AGONIST AND ITS USE

Also Published As

Publication number Publication date
CA3037146A1 (en) 2018-03-22
EP3512523A4 (en) 2020-05-06
EP3512523A1 (en) 2019-07-24
AU2017327383B2 (en) 2023-06-29
JP2022174261A (ja) 2022-11-22
AU2017327383A1 (en) 2019-04-11
US20190255080A1 (en) 2019-08-22
JP2019531346A (ja) 2019-10-31
KR20190060786A (ko) 2019-06-03
MX2023000887A (es) 2023-02-22
MX2019003032A (es) 2019-09-13
WO2018053036A1 (en) 2018-03-22
CN109922812A (zh) 2019-06-21

Similar Documents

Publication Publication Date Title
BR112019005039A2 (pt) método de redução dos efeitos colaterais associados à tireóide
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112017019170A2 (pt) métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
BR112016006733A2 (pt) método e aparelho para processamento de vídeo de vigilância
BR112017005453A2 (pt) compostos de aminopiridiloxipirazol
BR112017022772A2 (pt) métodos para tratar ou prevenir cefaleia de enxaqueca
BR112017024555A2 (pt) moduladores de ccr2
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
EA201791770A1 (ru) Фармацевтические композиции для комбинированной терапии
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112019023820A2 (pt) moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]